因良性前列腺增生转诊至门诊的患者特征:5815例全国前瞻性队列分析
基于意大利「IMPROVING THE PATH」项目的前瞻性横断面研究,纳入5815例良性前列腺增生门诊患者,比较已知诊断者与新诊断者的症状评分与合并症特征。已知诊断者更年长、吸烟饮酒及高血压、肥胖、糖尿病、心血管病更常见,IPSS中重度症状比例更高;新诊断者症状较轻,补充剂/植物药、α受体阻滞剂、5α还原酶抑制剂处方率分别为54.6%、21.6%、7.1%。
要点
- 5815例门诊患者中71.3%已知良性前列腺增生诊断,28.7%为本次就诊新诊断。
- 已知诊断者中重度IPSS症状比例高于新诊断者,新诊断者轻度症状比例更高,均p<0.001。
- 已知诊断者中63.5%被泌尿科医生调整至少一种正在使用的药物。
核心结论
- 尽管接受药物治疗,良性前列腺增生的自然病程仍导致症状进行性恶化。
- 新诊断与已知诊断患者之间生活方式和相关合并症的差异可能反映上述症状差异。
- 作者认为健康生活方式及含局部抗炎药物的治疗可能延缓症状恶化并改善生活质量。
研究设计与样本
- 「IMPROVING THE PATH」项目工作组设计问卷,由泌尿科医生前瞻性发放给良性前列腺增生门诊患者。
- 横断面研究,共纳入5815例患者。
- 数据按患者年龄作为潜在混杂因素进行校正。
主要发现
- 已知良性前列腺增生者4144例(71.3%),新诊断者1671例(28.7%)。
- 已知诊断者较新诊断者年龄更大(中位68岁 vs 55岁),吸烟(现吸烟27.2% vs 22.6%,既往吸烟16.4% vs 12.5%)及饮酒(55.4% vs 45.1%)更常见,高血压(60.0% vs 42.4%)、肥胖(15.3% vs 9.6%)、糖尿病(17.9% vs 12.5%)、心血管疾病(14.2% vs 9.5%)更常见,p<0.001。
- IPSS中度和重度症状与已知良性前列腺增生相关(中度56.1% vs 47.3%,重度24.8% vs 7.8%),新诊断者轻度症状更多(44.9% vs 19.1%),均p<0.001。
- BII中,对健康的担忧及因泌尿问题损失的时间在已知诊断者中更高(p<0.001)。
- 已知诊断者中63.5%被泌尿科医生调整至少一种正在使用的药物;新诊断者中补充剂/植物药、α受体阻滞剂、5α还原酶抑制剂处方率分别为54.6%、21.6%、7.1%。
临床怎么用
- 作者认为健康生活方式及含局部抗炎药物的治疗可能延缓症状恶化并改善生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on clinical presentation of benign prostatic hyperplasia (BPH) is scarce, and studies involving outpatients are lacking. We aimed to provide an insight into the contemporary Italian scenario of BPH-affected outpatients using symptom scores (International Prostate Symptom Score [IPSS], BPH Impact Index [BII]), and to compare characteristics of patients with known BPH and those first-diagnosed at the visit. METHODS: "IMPROVING THE PATH" project working group designed a questionary prospectively administered to BPH-affected outpatients by urologists. A cross-sectional study was performed. Data were adjusted for patient age as a potential confounding factor. RESULTS: Of 5815 patients enrolled, BPH was already diagnosed in 4144 (71.3%), and not in 1671 (28.7%). Patients with known BPH, compared to newly diagnosed, were older (median 68 versus [vs] 55), had more frequent smoking (smoker 27.2 vs 22.6%, and ex-smoker 16.4 vs 12.5%) and drinking habits (55.4 vs 45.1%), were more frequently affected by hypertension (60.0 vs 42.4%), obesity (15.3 vs 9.6%), diabetes (17.9 vs 12.5%), and cardiovascular diseases (14.2 vs 9.5%), p < 0.001. At IPSS, moderate and severe symptoms correlated with already known BPH (56.1 vs 47.3% and 24.8 vs 7.8%), whereas newly diagnosed patients showed milder symptoms (44.9 vs 19.1%), all p < 0.001. At BII, concern for one's health and time lost due to urinary problems were higher in patients with known BPH (p < 0.001). For these patients, the urologist changes at least one of the ongoing medications in 63.5%. For patients newly diagnosed, supplements/phytotherapeutics, alpha-blockers, and 5-alfa reductase inhibitors were prescribed in 54.6%, 21.6%, and 7.1%, respectively. CONCLUSIONS: Despite medical treatment, natural history of BPH leads to a progressive deterioration of symptoms. This may reflect the difference between newly diagnosed patients and those with known BPH in lifestyle and associated comorbidities. A healthy lifestyle and treatments including local anti-inflammatory agents may delay worsening of symptoms and improve quality of life.
引用
- Ornaghi PI, Porreca A, Sandri M, et al. Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases. Prostate Cancer Prostatic Dis. 2022. PMID: 35869394. doi:10.1038/s41391-022-00575-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。